[The RAAS and SARS-CoV-2: A riddle to solve]. / El SRAA y el SARS-CoV-2: el acertijo a resolver.
Hipertens Riesgo Vasc
; 37(4): 169-175, 2020.
Artigo
em Espanhol
| MEDLINE | ID: covidwho-1322115
ABSTRACT
The first case of COVID-19 was reported on 31 December 2019 in Wuhan, China. Ever since there has been unprecedented and growing interest in learning about all aspects of this new disease. Debate has been generated as to the association between antihypertensive therapy with renin-angiotensin-aldosterone system (RAAS) inhibitors and SARS-CoV-2 infection. While many questions as yet remain unanswered, the aim of this report is to inform health professionals about the current state of knowledge. Because this is an ever-evolving topic, the recommendation is that it be updated as new evidence becomes available. Below, we provide a review of pre-clinical and clinical studies that link coronavirus to the RAAS.
Palavras-chave
Angiotensin receptor blocker; Angiotensin-converting enzyme inhibitors; Antagonistas del receptor de angiotensina II; High blood pressure; Hipertensión arterial; Inhibidores de la enzima convertidora de angiotensina; Renin-angiotensin-aldosterone system; SARS-CoV-2; Sistema renina-angiotensina-aldosterona
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Sistema Renina-Angiotensina
/
Infecções por Coronavirus
/
Pandemias
/
Betacoronavirus
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Tópicos:
Covid persistente
/
Vacinas
Idioma:
Espanhol
Revista:
Hipertens Riesgo Vasc
Ano de publicação:
2020
Tipo de documento:
Artigo
País de afiliação:
J.hipert.2020.05.005
Similares
MEDLINE
...
LILACS
LIS